Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
August 06, 2024 17:50 ET
|
Agios Pharmaceuticals, Inc.
Agios will receive a total of $1.1 billion in milestone payments following the FDA approval of vorasidenib
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
August 01, 2024 06:31 ET
|
Agios Pharmaceuticals, Inc.
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905...
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
August 01, 2024 06:30 ET
|
Agios Pharmaceuticals, Inc.
– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – –...
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
June 15, 2024 08:45 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
June 06, 2024 09:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
June 03, 2024 06:30 ET
|
Agios Pharmaceuticals, Inc.
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key...
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 30, 2024 16:05 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
May 28, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain...
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
May 14, 2024 10:00 ET
|
Agios Pharmaceuticals, Inc.
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...